9 reports

  • ALGAE PRODUCTS MARKET SIZE, BY SOURCE, 2016-2023 (USD MILLION)
  • BROWN ALGAE PRODUCTS MARKET SIZE, BY REGION, 2016-2023 (USD MILLION)

PARRY ## ##. ## ##. ## B U S I N E S S O V E R V I E W E. I. D.

  • Dietary Supplement
  • United States
  • World
  • Market Size
  • Cargill Inc.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Dementia
  • Stroke
  • Therapy
  • United States
  • Product Initiative

One external remote patient monitoring device consists of one external module or transmitter.

  • Cardiovascular Disease
  • Dietary Supplement
  • Stroke
  • United States
  • Pfizer Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Dietary Supplement
  • Pharmaceutical
  • Stroke
  • Vitamin
  • World
  • Clinical Trial profile. 749 Trial Title
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Dietary Supplement
  • Endocrine Disease
  • Stroke
  • Vitamin
  • World
  • STROKE - PIPELINE BY SAVARA INC, H1 2018
  • STROKE - PIPELINE BY SHIN POONG PHARMCO LTD, H1 2018

The company provides cardiovascular, psychoneurotic, anti-cancer, antihistamine, antirheumatic and benign prostatic hyperplasia drugs.

  • Chronic Disease
  • Dietary Supplement
  • Stroke
  • Company
  • Product Initiative
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H1 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Research And Development
  • Stroke
  • United States
  • Company Operations
  • AB Science SA
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H2 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Dietary Supplement
  • Stroke
  • Therapy
  • Product Initiative
  • AB Science SA